FGA145
FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity[1].
Product Specifications
UNSPSC
12352005
Target
Cathepsin; SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/fga145.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H](C[C@@H]1CCNC1=O)/C=C/[N+]([O-])=O)[C@H](CC(C)C)NC(/C=C/C2=CC=CC=C2)=O
Molecular Formula
C23H30N4O5
Molecular Weight
442.51
References & Citations
[1]Medrano FJ, et al., Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2. Commun Chem. 2024 Jan 18;7 (1) :15.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cathepsin B; Cathepsin L
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6300457-01 0.2 mL
FXN, NT (FXN, FRDA, X25, Frataxin, mitochondrial, Friedreich ataxia protein, Frataxin intermediate form, Frataxin(56-210), m56-FXN, Frataxin(78-210), d-FXN, m78-FXN, Frataxin mature form, Frataxin(81-210), m81-FXN) (Biotin)
Ask
View Details MBS6300457-02 5x 0.2 mL
FXN, NT (FXN, FRDA, X25, Frataxin, mitochondrial, Friedreich ataxia protein, Frataxin intermediate form, Frataxin(56-210), m56-FXN, Frataxin(78-210), d-FXN, m78-FXN, Frataxin mature form, Frataxin(81-210), m81-FXN) (Biotin)
Ask
View Details